Enhanced S-Cone Syndrome and Other NR2E3-Related Retinal Dystrophies: Ocular Genetic Studies

Enhanced S-cone syndrome (ESCS) is a rare inherited retinal dystrophy characterized by a marked increase in S-cone cell function and simultaneous loss of rod photoreceptors. It typically presents in childhood with night blindness (nyctalopia) and may be misdiagnosed as retinitis pigmentosa or congenital stationary night blindness. The disease follows an autosomal recessive inheritance pattern and is caused by mutations in the NR2E3 gene, a nuclear receptor involved in retinal photoreceptor differentiation. These mutations disrupt normal development, leading to a retina dominated by S-cones and lacking functional rods. Clinically, ESCS progresses through distinct stages, starting with peripheral photoreceptor loss, followed by macular schisis and decrease in visual acuity, and finally retinal thinning with persistent vision impairment. Optical coherence tomography (OCT) and adaptive optics imaging reveal structural disruptions, including foveoschisis and abnormal layering. Electroretinography (ERG) shows absent rod responses and increased S-cone activity. Fundus findings include pigment clumping, yellow-white dots, macular changes, and, in some cases, subretinal fibrosis. Despite abnormal cone distribution, color vision can remain relatively intact. Currently, there is no cure for ESCS. Management focuses on treating complications like cystoid macular edema with carbonic anhydrase inhibitors, and addressing choroidal neovascularization with anti-VEGF agents. Gene therapy, particularly with CRISPR-Cas9 and AAV-based vectors, is under investigation. NR2E3 mutations are also linked to related disorders such as Goldmann-Favre syndrome, clumped pigmentary retinal degeneration, and retinitis pigmentosa, reflecting a spectrum of phenotypes. These overlapping conditions highlight the gene’s critical role in retinal development and degeneration. ESCS continues to be a valuable model for studying photoreceptor biology and exploring emerging genetic therapies.